Chemistry:Upamostat

From HandWiki
Short description: Chemical compound
Upamostat
Upamostat structure.png
Legal status
Legal status
  • Investigational new drug
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
Chemical and physical data
FormulaC32H47N5O6S
Molar mass629.82 g·mol−1
3D model (JSmol)

Upamostat (WX-671, Mesupron) is a drug which acts as an inhibitor of the serine protease enzyme urokinase. It is under development as a potential treatment agent for pancreatic cancer, acting to inhibit tumour metastasis.[1][2][3]

References

  1. "Benzamide and Benzamidine Compounds as New Inhibitors of Urokinasetype Plasminogen Activators". Mini Reviews in Medicinal Chemistry 18 (20): 1753–1758. 2018. doi:10.2174/1389557518666180816110740. PMID 30112993. 
  2. "Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer". British Journal of Cancer 108 (4): 766–70. March 2013. doi:10.1038/bjc.2013.62. PMID 23412098. 
  3. "Activation of the anti-cancer agent upamostat by the mARC enzyme system". Xenobiotica; the Fate of Foreign Compounds in Biological Systems 43 (9): 780–4. September 2013. doi:10.3109/00498254.2013.767481. PMID 23379481.